Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

• Sponsor: University of Washington (Other)
• Overall Status: Terminated
• CT.gov ID: NCT03256045
• Collaborator: National Cancer Institute (NCI) (NIH), SecuraBio (Industry)
• Enrollment: 9
• Location: 1
• Arm: 1
• Actual Duration (Months): 35.9
• Patients Per Site Per Month: 0.3

Study Details

Study Description

Brief Summary

This phase II trial studies how well panobinostat, carfilzomib, and dexamethasone work in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as carfilzomib and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Using multiple myeloma cells from patients' blood samples, the researchers will do laboratory tests to look at how well each of the drugs, alone and in different combinations, kill multiple myeloma cells. If the laboratory tests work well, they may be used in the future to help plan treatment for future patients.

Condition or Disease	Intervention/Treatment	Phase
Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma	Drug: Carfilzomib; Other: Chemosensitivity Assay; Drug: Dexamethasone; Other: Laboratory Biomarker Analysis; Drug: Panobinostat	Phase 2

Detailed Description

PRIMARY OBJECTIVE:

1. To correlate in vitro drug sensitivity testing with clinical response by determining the rate of in vitro drug sensitivity to panobinostat, carfilzomib, and dexamethasone singly and in combination, doublets and triplets.

SECONDARY OBJECTIVE:

1. To monitor response rates (partial response [PR], very good partial response [VGPR], and complete response) using the International Myeloma Working Group Uniform Response Criteria for Multiple Myeloma.

EXPLORATORY OBJECTIVE:

1. Progression free survival and overall survival will be assessed for up to 3 years after last dose.

OUTLINE:

Patients receive panobinostat orally (PO) on days 1, 3, 5, 15, 17, and 19. Patients also receive carfilzomib intravenously (IV) and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay.

After completion of study treatment, patients are followed up every 3 months for up to 3 years.

Study Design

• Study Type: Interventional
• Actual Enrollment: 9 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: CLBH589DUS108T: Panobinostat With Carfilzomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Correlation With In Vitro Chemosensitivity Testing
• Actual Study Start Date: Feb 8, 2018
• Actual Primary Completion Date: Feb 5, 2021
• Actual Study Completion Date: Feb 5, 2021

Arms and Interventions

Arm

Intervention/Treatment

Experimental: Treatment-panobinostat, carfilzomib, dexamethasone,chemo assay Patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19. Patients also receive carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay.

Drug: Carfilzomib; Given IV; Other Names: Kyprolis PR-171 ; Other: Chemosensitivity Assay; Undergo in vitro chemosensitivity testing; Other Names: Chemosensitivity Testing ; Drug: Dexamethasone; Given PO; Other Names: Aacidexam Adexone Aknichthol Dexa Alba-Dex Alin Alin Depot Alin Oftalmico Amplidermis Anemul mono Auricularum Auxiloson Baycuten Baycuten N Cortidexason Cortisumman Decacort Decadrol Decadron Decalix Decameth Decasone R.p. Dectancyl Dekacort Deltafluorene Deronil Desamethasone Desameton Dexa-Mamallet Dexa-Rhinosan Dexa-Scheroson Dexa-sine Dexacortal Dexacortin Dexafarma Dexafluorene Dexalocal Dexamecortin Dexameth Dexamethasonum Dexamonozon Dexapos Dexinoral Dexone Dinormon Fluorodelta Fortecortin Gammacorten Hexadecadrol Hexadrol Lokalison-F Loverine Methylfluorprednisolone Millicorten Mymethasone Orgadrone Spersadex Visumetazone ; Other: Laboratory Biomarker Analysis; Correlative studies; Drug: Panobinostat; Given PO; Other Names: Faridak Farydak LBH589

Outcome Measures

Primary Outcome Measures

1. Best Overall Response, by Subject [14 months]

   Assessed using the International Myeloma Working Group Uniform Response Criteria for Multiple Myeloma. Key: 1 = very good partial response (VGPR); 2 = partial response (PR); 3 = minimal response (MR); 4 = stable disease (SD); 5 = progressive disease (PD). Please see IC50 and CI results in the other primary outcome measures.

2. Multiple Myeloma Cells In-vitro Drug Sensitivity to Panobinostat, by Subject [At baseline]

   Multiple myeloma cells are added to assay with panobinostat. Cell viability and IC50 is determined. IC50 is the inhibitory concentration that kills 50% of cells. Results are reported in concentrations E-9.

3. Multiple Myeloma Cells In-vitro Drug Sensitivity to Carfilzomib, by Subject [At baseline]

   Multiple myeloma cells are added to assay with carfilzomib. Cell viability and IC50 is determined. IC50 is the inhibitory concentration that kills 50% of cells.

4. Multiple Myeloma Cells In-vitro Drug Sensitivity to Dexamethasone, by Subject [At baseline]

   Multiple myeloma cells are added to assay with dexamethasone. Cell viability and IC50 is determined. IC50 is the inhibitory concentration that kills 50% of cells. Results are reported in concentrations E-6.

5. Synergy of Panobinostat and Carfilzomib in Combination, Per Subject. [At baseline]

   Concentration of carfilzomib and panobinostat in combination leading to 90% growth inhibition of multiple myeloma cells in-vitro. The combination index (CI) is calculated using formula: CI = ([D1] in the combination / [D1] alone) + ([D2] in the combination / [D2] alone). Key: CI = 1 no synergy; CI<1 synergy; CI>1 antagonism.

6. Synergy of Panobinostat and Dexamethasone in Combination, Per Subject [At baseline]

   Concentration of panobinostat and dexamethasone in combination leading to 90% growth inhibition of multiple myeloma cells in-vitro. The combination index (CI) is calculated using formula: CI = ([D1] in the combination / [D1] alone) + ([D2] in the combination / [D2] alone). Key: CI = 1 no synergy; CI<1 synergy; CI>1 antagonism.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Diagnosis of multiple myeloma refractory to or relapsed after >= 1 line of prior therapy (International Myeloma Working Group [IMWG] criteria)

• Measurable disease, as indicated by one of the following:

• Serum monoclonal (M)-protein >= 1.0 g/dL

• Elevated involved free light chain >= 10 mg/dL as per IMWG criteria, and abnormal ratio

• Urine Bence Jones protein > 200 mg/24 hour (hr)

• Absolute neutrophil count (ANC) >= 750/uL

• Platelet count >= 75,000/uL

• Hemoglobin >= 7 g/dL

• Creatinine =< 2.0 mg/dL or calculated creatinine clearance >= 30 mL/min

• Total bilirubin =< 1.5 x upper limit of normal (ULN) unless elevation is thought to be due to Gilbert's syndrome

• Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamate pyruvate transaminase (SPGT) (alanine aminotransferase [ALT]) =< 2.5 x ULN

• Patients must avoid consumption of grapefruit, pomegranates, starfruit, Seville oranges or products containing the juice of each during the entire study and preferably 7 days before the first dose of study medications; orange juice is allowed

• Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, should have a pregnancy test prior to the initiation of treatment and use highly effective methods of contraception during and for 3 months post study treatment; highly effective contraception methods include total abstinence, female sterilization, male sterilization, use of oral, injected, or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy; women using hormonal contraceptives should additionally use a barrier method of contraception; women are considered post-menopausal and not of child-bearing potential if they have had 12 months of natural amenorrhea or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks ago

• Sexually active males must use a condom during intercourse while taking study drug and for 6 months after stopping treatment; males should not father a child in this period; a condom is required to be used also by vasectomized men as well as during intercourse with a male partner; female partners of sexually active men should also use an effective contraception during treatment and for 6 months after their male partner has stopped taking the drug

Exclusion Criteria:

• Another bone marrow malignancy

• Another cancer with expected survival of < 2 years

• Active viral, bacterial, or fungal infection progressing on current treatment

• Clinically significant uncontrolled heart disease and/or recent cardiac event within 6 months prior to enrollment, such as:

• History of angina pectoris, symptomatic pericarditis, or myocardial infarction

• Left ventricular ejection fraction (LVEF) < 45% as determined by echocardiogram (ECHO) or multi gated acquisition (MUGA) scan

• History or presence of any significant, uncontrolled, or persistent cardiac arrhythmias, e.g. ventricular, supraventricular, nodal arrhythmias or conduction abnormality; stable atrial fibrillation within 6 months prior to randomization is permitted

• Presence of unstable atrial fibrillation (ventricular response rate > 100 beats per minute [bpm]); NOTE: patients with stable atrial fibrillation can be enrolled provided they do not meet other cardiac exclusion criteria

• Resting heart rate < 50 bpm

• Complete left bundle branch block (LBBB), bifascicular block

• Congenital long QT syndrome

• Any clinically significant ST segment and/or T-wave abnormalities

• Corrected QT (QTcF) > 450 msec for males and > 470 msec for females using Fridericia's correction on screening electrocardiogram (ECG)

• History of documented congestive heart failure (New York Heart Association functional classification III-IV)

• Uncontrolled hypertension defined by a systolic blood pressure (SBP) >= 150 mmHg and/or diastolic blood pressure (DBP) >= 100 mmHg with or without antihypertensive medication; NOTE: initiation or adjustment of antihypertensive medication(s) is allowed prior to screening

• Other clinically significant heart disease or vascular disease

• Currently taking medications that have known or definite risk of prolonging the QT interval or inducing Torsades de pointes (TdP); the medication must be discontinued or switched to a safe alternative medication prior to starting treatment; specific exception is allowed for patients on long-standing medications that have risk of prolonging QT interval or inducing TdP if screening ECG does not indicate a prolonged QT abnormality

• Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat or dexamethasone (e.g. ulcerative disease uncontrolled nausea, vomiting, malabsorption syndrome, obstruction, or stomach and/or small bowel resection)

• Unresolved diarrhea >= Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or a medical condition associated with chronic diarrhea (such as irritable bowel syndrome, inflammatory bowel disease)

• Major surgery =< 14 days prior to starting study treatment or side effects of surgery that have not recovered to < CTCAE grade 2

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Fred Hutch/University of Washington Cancer Consortium	Seattle	Washington	United States	98109

Sponsors and Collaborators

• University of Washington
• National Cancer Institute (NCI)
• SecuraBio

Investigators

• Principal Investigator: Andrew Cowan, Fred Hutch/University of Washington Cancer Consortium

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Dec 22, 2021

More Information

Publications

None provided.

• Responsible Party: Andrew Cowan, Assistant Professor, Division of Medical Oncology, University of Washington
• ClinicalTrials.gov Identifier: NCT03256045
• Other Study ID Numbers: 9757; NCI-2017-00453; 9757; P30CA015704; RG1016013
• First Posted: Aug 21, 2017
• Last Update Posted: May 9, 2022
• Last Verified: May 1, 2022

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Multiple Myeloma; Neoplasms, Plasma Cell; Dexamethasone; Dexamethasone acetate; Panobinostat; Ichthammol; BB 1101

Study Results

Participant Flow

Arm/Group Title	Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone
Arm/Group Description	Patients undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay. Regardless of assay results, patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19, and carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
Period Title: Overall Study
STARTED	9
COMPLETED	9
NOT COMPLETED	0

Baseline Characteristics

Arm/Group Title	Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone
Arm/Group Description	Patients undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay. Regardless of assay results, patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19, and carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
Overall Participants	9
Age, Customized (years) [Median (Full Range) ]
Median (Full Range) [years]	67
Sex/Gender, Customized (Count of Participants)
Male	6 66.7%
Female	3 33.3%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	1 11.1%
Not Hispanic or Latino	8 88.9%
Unknown or Not Reported	0 0%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%
Asian	0 0%
Native Hawaiian or Other Pacific Islander	0 0%
Black or African American	0 0%
White	9 100%
More than one race	0 0%
Unknown or Not Reported	0 0%
Prior therapy regimes (number of regimens) [Median (Full Range) ]
Median (Full Range) [number of regimens]	5
Prior autologous transplant (percentage of participants) [Number]
Number [percentage of participants]	88.9 987.8%
Revised ISS Stage (ISS Stage) [Median (Full Range) ]
Median (Full Range) [ISS Stage]	2.5

Outcome Measures

1. Primary Outcome

Title	Best Overall Response, by Subject
Description	Assessed using the International Myeloma Working Group Uniform Response Criteria for Multiple Myeloma. Key: 1 = very good partial response (VGPR); 2 = partial response (PR); 3 = minimal response (MR); 4 = stable disease (SD); 5 = progressive disease (PD). Please see IC50 and CI results in the other primary outcome measures.
Time Frame	14 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone
Arm/Group Description	Patients undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay. Regardless of assay results, patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19, and carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
Measure Participants	9
Subject MM-82	4
Subject MM-91	2
Subject MM-92	2
Subject MM-95	1
Subject MM-96	1
Subject MM-98	1
Subject MM-99	3
Subject MM-109	4
Subject M-111	1

2. Primary Outcome

Title	Multiple Myeloma Cells In-vitro Drug Sensitivity to Panobinostat, by Subject
Description	Multiple myeloma cells are added to assay with panobinostat. Cell viability and IC50 is determined. IC50 is the inhibitory concentration that kills 50% of cells. Results are reported in concentrations E-9.
Time Frame	At baseline

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone
Arm/Group Description	Patients undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay. Regardless of assay results, patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19, and carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
Measure Participants	9
Subject MM-82	3.8
Subject MM-91	5.9
Subject MM-92	2.6
Subject MM-95	19.8
Subject MM-96	1.3
Subject MM-98	4.4
Subject MM-99	8.5
Subject MM-109	13.6
Subject MM-111	2.0

3. Primary Outcome

Title	Multiple Myeloma Cells In-vitro Drug Sensitivity to Carfilzomib, by Subject
Description	Multiple myeloma cells are added to assay with carfilzomib. Cell viability and IC50 is determined. IC50 is the inhibitory concentration that kills 50% of cells.
Time Frame	At baseline

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone
Arm/Group Description	Patients undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay. Regardless of assay results, patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19, and carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
Measure Participants	9
Subject MM-82	17.5
Subject MM-91	0.479
Subject MM-92	0.03
Subject MM-95	0.269
Subject MM-96	0.0048
Subject MM-98	0.159
Subject MM-99	0.159
Subject MM-109	0.108
Subject MM-111	0.0152

4. Primary Outcome

Title	Multiple Myeloma Cells In-vitro Drug Sensitivity to Dexamethasone, by Subject
Description	Multiple myeloma cells are added to assay with dexamethasone. Cell viability and IC50 is determined. IC50 is the inhibitory concentration that kills 50% of cells. Results are reported in concentrations E-6.
Time Frame	At baseline

Outcome Measure Data

Analysis Population Description

Results for subject MM-92 were not reported.

Arm/Group Title	Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone
Arm/Group Description	Patients undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay. Regardless of assay results, patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19, and carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
Measure Participants	8
Subject MM-82	3.7
Subject MM-91	10.9
Subject MM-95	7
Subject MM-96	1.1
Subject MM-98	14.8
Subject MM-99	8.6
Subject MM-109	80
Subject MM-111	1.1

5. Primary Outcome

Title	Synergy of Panobinostat and Carfilzomib in Combination, Per Subject.
Description	Concentration of carfilzomib and panobinostat in combination leading to 90% growth inhibition of multiple myeloma cells in-vitro. The combination index (CI) is calculated using formula: CI = ([D1] in the combination / [D1] alone) + ([D2] in the combination / [D2] alone). Key: CI = 1 no synergy; CI<1 synergy; CI>1 antagonism.
Time Frame	At baseline

Outcome Measure Data

Analysis Population Description

CI score was not reported for subject MM-82.

Arm/Group Title	Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone
Arm/Group Description	Patients undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay. Regardless of assay results, patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19, and carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
Measure Participants	8
Subject MM-91	2.5
Subject MM-92	2.4
Subject MM-95	0.3
Subject MM-96	2.2
Subject MM-98	2.6
Subject MM-99	1.8
Subject MM-109	1.7
Subject MM-111	62.2

6. Primary Outcome

Title	Synergy of Panobinostat and Dexamethasone in Combination, Per Subject
Description	Concentration of panobinostat and dexamethasone in combination leading to 90% growth inhibition of multiple myeloma cells in-vitro. The combination index (CI) is calculated using formula: CI = ([D1] in the combination / [D1] alone) + ([D2] in the combination / [D2] alone). Key: CI = 1 no synergy; CI<1 synergy; CI>1 antagonism.
Time Frame	At baseline

Outcome Measure Data

Analysis Population Description

CI score was not reported for subject MM-82

Arm/Group Title	Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone
Arm/Group Description	Patients undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay. Regardless of assay results, patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19, and carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
Measure Participants	8
Subject MM-91	1.3
Subject MM-92	2.6
Subject MM-95	1.4
Subject MM-96	0.6
Subject MM-98	1.2
Subject MM-99	0.9
Subject MM-109	4.6
Subject MM-111	1.2

Adverse Events

Time Frame	Adverse events after any administration of the study drug through 30 days after the last administration of therapy will be recorded and followed until resolution.
Adverse Event Reporting Description	Only non-hematologic toxicities ≥ grade 3 will be reported as adverse events. Hospitalizations or prolongation of hospitalizations for protocol-schedule procedures, blood product transfusions, or social reasons (i.e. awaiting transport home) will not be considered a SAE.
Arm/Group Title	Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone
Arm/Group Description	Patients undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay. Regardless of assay results, patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19, and carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
All Cause Mortality
	Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone
	Affected / at Risk (%)	# Events
Total	0/9 (0%)
Serious Adverse Events
	Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone
	Affected / at Risk (%)	# Events
Total	3/9 (33.3%)
Cardiac disorders
Non-ST segment elevation myocardial infarction	1/9 (11.1%)	1
Injury, poisoning and procedural complications
Fracture, pathologic	1/9 (11.1%)	1
Fracture, non-pathologic	1/9 (11.1%)	1
Fall	1/9 (11.1%)	1
Other (Not Including Serious) Adverse Events
	Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone
	Affected / at Risk (%)	# Events
Total	4/9 (44.4%)
Gastrointestinal disorders
Diarrhea	1/9 (11.1%)	1
Nervous system disorders
Syncope	1/9 (11.1%)	1
Vascular disorders
Hypertension	2/9 (22.2%)	2

Limitations/Caveats

Study was limited by lower accrual than expected due to: competing studies, other investigators' treatment preferences, and ultimately, the departure of the initial PI from the institution. Because of PI's departure and lab closure, the study closed to accrual after the 9th patient enrolled. Because only 9 subjects were enrolled and some in-vitro assay results are unavailable, it is difficult to analyze the in-vitro assay results and determine the parameters that predict disease response.

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.